vinpocetine has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arava, SK; Arora, T; Kaur, T; Kumar, N; Shah, S; Singh, AP; Vishwakarma, VK; Yadav, HN; Yadav, RK; Yadav, S | 1 |
| Li, JD; Wu, MP; Xu, X; Yan, C; Zhang, YS; Zhou, Q | 1 |
2 other study(ies) available for vinpocetine and Cirrhosis
| Article | Year |
|---|---|
Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats: possible involvement of PDE-1/TGF-β/ Smad 2/3 signalling pathways.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Enalapril; Fibrosis; Humans; Phosphoric Diester Hydrolases; Rats; Signal Transduction; Transforming Growth Factor beta | 2023 |
Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiomyopathies; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 1; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Signal Transduction; Ventricular Remodeling; Vinca Alkaloids | 2017 |